help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on March 23, 2006
Endocrinology, doi:10.1210/en.2006-0147
A more recent version of this article appeared on June 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
147/6/2650    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rondinone, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rondinone, C. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes
*Nutrition
*Obesity

Submitted on February 6, 2006
Accepted on March 7, 2006

RNAi for the Identification of New Targets for the Treatment of Metabolic Diseases

Cristina M. Rondinone*

Department Metabolic Diseases, Hoffmann-La Roche, Nutley, New Jersey 07110, USA

* To whom correspondence should be addressed. E-mail: cristina.rondinone{at}roche.com.

Over the past years RNA interference (RNAi) has exploded as a new approach to manipulate gene expression in mammalian systems. More recently, RNAi has acquired interest as a tool to identify new targets for therapeutic intervention. This review focuses on the current understanding of RNAi biology, how RNAi has been used to study the role of different genes in the pathogenesis of diabetes and obesity and the use of RNAi screens for the identification of new targets for metabolic diseases. Also reviewed are the in vivo proof-of-principle experiments that provide the validation of these new targets for the development of RNAi-based therapeutics for diabetes.
Key words: RNA interference • diabetes • insulin signaling • target discovery






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society